U.S. markets close in 2 hours 3 minutes
  • S&P 500

    3,250.13
    -59.98 (-1.81%)
     
  • Dow 30

    26,276.00
    -383.11 (-1.44%)
     
  • Nasdaq

    10,864.84
    -320.76 (-2.87%)
     
  • Russell 2000

    1,536.15
    -25.43 (-1.63%)
     
  • Crude Oil

    35.34
    -0.83 (-2.29%)
     
  • Gold

    1,878.10
    +10.10 (+0.54%)
     
  • Silver

    23.60
    +0.24 (+1.03%)
     
  • EUR/USD

    1.1648
    -0.0030 (-0.26%)
     
  • 10-Yr Bond

    0.8550
    +0.0200 (+2.40%)
     
  • GBP/USD

    1.2948
    +0.0025 (+0.19%)
     
  • USD/JPY

    104.6390
    +0.0290 (+0.03%)
     
  • BTC-USD

    13,505.39
    +206.54 (+1.55%)
     
  • CMC Crypto 200

    263.87
    +0.23 (+0.09%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

BURNABY, British Columbia, May 29, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Jefferies 2019 Healthcare Conference in New York, NY on Wednesday, June 5, 2019 at 11:00 am ET.

A live webcast will be available on the investors section of Xenon's website at www.xenon-pharma.com and will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com